Alfuzosin Hydrochloride Tablet, Extended Release
Product Images NDC 76282-302

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 76282-302). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Alf4 (Alf4)

A line graph showing Alfuzosin plasma concentration (ng/mL) over 24 hours with two conditions, fed and fasted. The y-axis represents drug concentration and the x-axis shows time in hours, illustrating higher plasma levels under fed conditions compared to fasted.*

FDA Label Image

Alf8 (Alf8)

Label for Alfuzosin HCl Extended-Release Tablets, USP 10 mg by Exelan Pharmaceuticals Inc. The label specifies a package containing 100 extended-release oral tablets. It includes storage instructions, manufacturing details (InvaGen Pharmaceuticals, a Cipla Ltd. subsidiary), and a barcode. The label also advises dispensing with a patient information leaflet.*

FDA Label Image

Dia1 (Dia1)

Chemical structure of alfuzosin hydrochloride, showing its molecular arrangement including aromatic rings, amine groups, and hydrochloride salt.*

FDA Label Image

Dia10 (Dia10)

A line graph showing mean change (mL/s) over days of treatment comparing Alfuzosin hydrochloride (N=136) and placebo (N=147). The graph indicates a higher mean change for the Alfuzosin HCl group across 14, 28, 56, and 84 days, with statistically significant difference at day 84.*

FDA Label Image

Dia11 (Dia11)

A line chart comparing mean change over days of treatment between a placebo group (N=150) and an Alfuzosin hydrochloride group (N=151). The x-axis represents days of treatment (0, 14, 28, 56, 84), and the y-axis shows mean change values in mL/s. The Alfuzosin group shows a higher mean change over time compared to placebo, with statistical notation indicating no significant difference (NS, p > 0.05).*

FDA Label Image

Dia6 (Dia6)

A line graph showing mean change over days of treatment comparing placebo and Alfuzosin hydrochloride groups. The x-axis represents days of treatment (0, 28, 56, 84), and the y-axis shows mean change. The graph includes two lines for placebo (N=167) and Alfuzosin HCl (N=170), indicating a statistically significant difference (p < 0.001) favoring Alfuzosin HCl over placebo during the treatment period.*

FDA Label Image

Dia7 (Dia7)

A line graph comparing median change over 84 days of treatment between placebo and Alfuzosin HCl groups. The x-axis represents days of treatment (0, 28, 56, 84), and the y-axis represents median change. The graph shows greater median change decrease in the Alfuzosin HCl group compared to placebo, with statistical significance noted at day 84 (p < 0.01).*

FDA Label Image

Dia8 (Dia8)

A line graph comparing the mean change over days of treatment between two groups: one receiving placebo and the other receiving Alfuzosin hydrochloride (HCl). The x-axis shows days of treatment (0, 28, 56, 84), and the y-axis indicates mean change values. The graph illustrates a greater decrease in mean values with Alfuzosin HCl compared to placebo. Statistical significance is indicated with p < 0.01.*

FDA Label Image

Dia9 (Dia9)

A line graph showing mean change in mL/s over days of treatment for Alfuzosin hydrochloride versus placebo. The graph compares data points at 0, 28, 56, and 84 days, with Alfuzosin HCl showing consistently higher mean changes than placebo. A statistical significance marker indicates p < 0.001.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.